An in-frame deletion in Kir6.2 (KCNJ11) causing neonatal diabetes reveals a site of interaction between Kir6.2 and SUR1.
BACKGROUND
Activating mutations in genes encoding the Kir6.2 (KCNJ11) and SUR1 (ABCC8) subunits of the pancreatic ATP-sensitive K(+) channel are a common cause of permanent neonatal diabetes (PNDM). All Kir6.2 mutations identified to date are missense mutations. We describe here a novel in-frame deletion (residues 28-32) in Kir6.2 in a heterozygous patient with PNDM without neurological problems that are detectable by standard evaluation.


OBJECTIVE
The aim of the study was to identify the mutation responsible for neonatal diabetes in this patient and characterize its functional effects.


METHODS
Wild-type and mutant Kir6.2/SUR1 channels were examined by heterologous expression in Xenopus oocytes.


RESULTS
The Kir6.2-28Delta32 mutation produced a significant decrease in ATP inhibition and an increase in whole-cell K(ATP) currents, explaining the diabetes of the patient. Tolbutamide block was only slightly reduced in the simulated heterozygous state, suggesting that the patient should respond to sulfonylurea therapy. The mutation decreased ATP inhibition indirectly, by increasing the intrinsic (unliganded) channel open probability. Neither effect was observed when Kir6.2 was expressed in the absence of SUR1, suggesting that the mutation impairs coupling between SUR1 and Kir6.2. Coimmunoprecipitation studies further revealed that the mutation disrupted a physical interaction between Kir6.2 and residues 1-288 (but not residues 1-196) of SUR1.


CONCLUSIONS
We report a novel KCNJ11 mutation causing PNDM. Our results show that residues 28-32 in the N terminus of Kir6.2 interact both physically and functionally with SUR1 and suggest that residues 196-288 of SUR1 are important in this interaction.
Henry Wellcome Centre for Gene Function, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom.
Tim J
TJ
Craig
Kenju
K
Shimomura
Reinhard W
RW
Holl
Sarah E
SE
Flanagan
Sian
S
Ellard
Frances M
FM
Ashcroft
D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D003924:Diabetes Mellitus, Type 2 / Q000151:congenital / Q000235:genetics* / Q000378:metabolism; D017353:Gene Deletion; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000235:genetics*; D008297:Male; D008954:Models, Biological; D016366:Open Reading Frames / Q000235:genetics; D024661:Potassium Channels, Inwardly Rectifying / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology; D011485:Protein Binding / Q000235:genetics; D011955:Receptors, Drug / Q000378:metabolism*; D064233:Sulfonylurea Receptors; D014981:Xenopus; D000099161:Kcnj11 Channel
D018528:ATP-Binding Cassette Transporters; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D064233:Sulfonylurea Receptors; D000099161:Kcnj11 Channel; C577507:ABCC8 protein, human